{"entity":{"id":"vepugratinib","kind":"drug","name":"Vepugratinib","aka":[],"tldr":"Vepugratinib is an experimental small-molecule drug from Eli Lilly and in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.","summary":"Vepugratinib is a small-molecule drug developed by Eli Lilly and. The sponsor describes its target as FGFR3, which OnCo does not yet have a target page for. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07218380 (A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract), in bladder & urothelial cancer. The largest, NCT07218380, plans to enrol 450 participants with primary completion expected 2029-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Vepugratinib","url":"https://clinicaltrials.gov/search?intr=Vepugratinib"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07218380"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/vepugratinib/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"trial":[{"id":"nct07218380","kind":"trial","name":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","route":"/trials/nct07218380/"}]}}